SIRPant Immunotherapeutics Overview
- Founded
-
2020
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$25M
- Investors
-
3
SIRPant Immunotherapeutics General Information
Description
Developer of cancer-specific immunotherapy intended for the treatment of solid tumors. The company employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells resulting in a polyclonal immune response against multiple tumor antigens, enabling the medical community to improve treatment outcomes related to cancer.
Contact Information
Website
www.sirpantimmunotx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
- 1214 Research Boulevard
- Suite 2010
- Hummelstown, PA 17036
- United States
+1 (610) 000-0000
SIRPant Immunotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 29-Sep-2021 | $25M | 0000 | 0000 | Completed | Generating Revenue |
SIRPant Immunotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
SIRPant Immunotherapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer-specific immunotherapy intended for the treatment of solid tumors. The company employs an Adoptive C
Drug Discovery
Hummelstown, PA
5
As of 2022
0000
000
0000-00-00
00000000000
0000
000000
adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mini
0000 000000000
Philadelphia, PA
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
0000 0
ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000 000000000
Brisbane, CA
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
Add Comparison
SIRPant Immunotherapeutics Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Carisma Therapeutics | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 0000 00000000 | Venture Capital-Backed | Brisbane, CA | 00 | 00000 | 00000000000 | 00000 |
| 000 00000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 00000000 | 00000 |
| 0000000000 000000 | Venture Capital-Backed | Windsor, United Kingdom | 0 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | Bedford, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
SIRPant Immunotherapeutics Executive Team (5)
SIRPant Immunotherapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| John Fucci | Bios Partners | Board Member | 000 0000 |
| Rifat Pamukcu MD | Self | Board Member | 000 0000 |
| Travis Whitfull | Self | Board Member | 000 0000 |
SIRPant Immunotherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
SIRPant Immunotherapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BioAdvance | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Bios Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| GRA Venture Fund | Venture Capital | Minority | 000 0000 | 000000 0 |